| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |